BR9812540A - Expressão de genes endógenos por recombinaçãonão homóloga de uma construção de vetor comdna celular - Google Patents
Expressão de genes endógenos por recombinaçãonão homóloga de uma construção de vetor comdna celularInfo
- Publication number
- BR9812540A BR9812540A BR9812540-0A BR9812540A BR9812540A BR 9812540 A BR9812540 A BR 9812540A BR 9812540 A BR9812540 A BR 9812540A BR 9812540 A BR9812540 A BR 9812540A
- Authority
- BR
- Brazil
- Prior art keywords
- expression
- gene
- genes
- cell
- methods
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 13
- 230000014509 gene expression Effects 0.000 title abstract 7
- 230000006801 homologous recombination Effects 0.000 title 1
- 238000002744 homologous recombination Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 102000035160 transmembrane proteins Human genes 0.000 abstract 3
- 108091005703 transmembrane proteins Proteins 0.000 abstract 3
- 230000010354 integration Effects 0.000 abstract 2
- 238000002955 isolation Methods 0.000 abstract 2
- 238000005215 recombination Methods 0.000 abstract 2
- 230000006798 recombination Effects 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000002299 complementary DNA Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Abstract
"EXPRESSãO DE GENES ENDóGENOS POR RECOMBINAçãONãO HOMOLOGA DE UMA CONSTRUçãO DE VETOR COMDNA CELULAR". A presente invenção refere-se, de modo geral, aativação da expressão de gene ou levando a expressão emexcesso de um gene por processos de recombinação in situ. Ainvenção também refere-se, de modo geral, aos processos paraexpressão de um gene endógeno, em uma célula, em níveis maisaltos do que aqueles normalmente encontrados na célula. Em umaconcretização da invenção, a expressão de um gene endógeno éativada ou aumentada seguindo-se integração na célula, porrecombinação não homóloga ou ilegítima, de uma seq³ênciareguladora que ativa a expressão do gene. Em outraconcretização, a expressão do gene endógeno pode seradicionalmente aumentada por co-integração de um ou maismarcadores ampliáveis e seleção das cópias aumentadas de umou mais marcadores ampliáveis localizados no vetor integrado. Ainvenção também provê processos para identificação e expressãodos genes que ainda não foram descobertos por processos atuais,uma vez que nenhuma seq³ência alvo é necessária paraintegração. A invenção também provê processos para isolamentodas moléculas de ácido nucléico (especificamente moléculas deCDNA) codificando proteínas de transmembrana e para isolamentodas células expressando tais proteínas de transmembrana, quepodem ser proteínas de transmembrana heterólogas. A invençãotambém refere-se aos genes isolados, produtos de gene, moléculasde ácido nucléico e composições compreendendo tais genes,produtos de gene e moléculas de ácido nucléico, que podem serusados em várias aplicações terapêuticas e de diagnóstico. Assim,pela presente invenção, os genes endógenos incluindo aquelesassociados com doença humana e desenvolvimento, podem serativados e isolados sem conhecimento precedente da seq³ência,estrutura, função ou perfil de expressão dos genes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94122397A | 1997-09-26 | 1997-09-26 | |
| US15964398A | 1998-09-24 | 1998-09-24 | |
| PCT/US1998/020094 WO1999015650A1 (en) | 1997-09-26 | 1998-09-25 | Expression of endogenous genes by non-homologous recombination of a vector construct with cellular dna |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9812540A true BR9812540A (pt) | 2001-12-26 |
Family
ID=26856150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9812540-0A BR9812540A (pt) | 1997-09-26 | 1998-09-25 | Expressão de genes endógenos por recombinaçãonão homóloga de uma construção de vetor comdna celular |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP1017803B1 (pt) |
| JP (1) | JP5377806B2 (pt) |
| KR (1) | KR20010024296A (pt) |
| CN (1) | CN100582230C (pt) |
| AT (1) | ATE471373T1 (pt) |
| AU (1) | AU750025B2 (pt) |
| BR (1) | BR9812540A (pt) |
| CA (1) | CA2304642C (pt) |
| DE (1) | DE69841723D1 (pt) |
| DK (1) | DK1017803T3 (pt) |
| IL (2) | IL135242A0 (pt) |
| NO (1) | NO20001497L (pt) |
| NZ (1) | NZ504185A (pt) |
| WO (1) | WO1999015650A1 (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6740503B1 (en) | 1997-09-26 | 2004-05-25 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
| US6897066B1 (en) | 1997-09-26 | 2005-05-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
| CA2364267A1 (en) * | 1999-02-19 | 2000-08-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
| EP1305412A2 (en) | 1999-10-14 | 2003-05-02 | Clontech Laboratories Inc. | Anthozoa derived chromo/fluoroproteins and methods for using the same |
| ES2317917T3 (es) | 2000-06-28 | 2009-05-01 | Amgen Inc. | Moleculas de receptor de linfopoyetina estromal timica y sus usos de las mismas. |
| GB0018876D0 (en) * | 2000-08-01 | 2000-09-20 | Applied Research Systems | Method of producing polypeptides |
| EP1352060A2 (en) * | 2000-10-30 | 2003-10-15 | Novozymes Biotech, Inc. | Methods for expressing endogenous genes by restriction enzyme mediated integration |
| DK1451295T3 (en) * | 2001-11-02 | 2015-07-06 | Athersys Inc | METHODS FOR MUTATION OF GENES IN CELLS AND ANIMALS USING THE INSERTION MUTAGENES. |
| ES2329666T3 (es) | 2001-12-19 | 2009-11-30 | The University Of Chicago | Proteinas fluorescentes de maduracion rapida y procedimientos de uso de las mismas. |
| US7662924B2 (en) | 2002-02-22 | 2010-02-16 | The Board Of Trustees Of The University Of Illinois | Beta chain-associated regulator of apoptosis |
| EP3170890A1 (en) | 2002-08-21 | 2017-05-24 | Revivicor, Inc. | Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase |
| US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
| WO2004071462A2 (en) | 2003-02-12 | 2004-08-26 | Johns Hopkins University | Methods and compositions for treatment of viral infections based on tsg101-vps28 interaction |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US11311574B2 (en) | 2003-08-08 | 2022-04-26 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
| ES2680569T3 (es) | 2004-03-17 | 2018-09-10 | Revivicor Inc. | Productos de tejidos derivados de animales que carecen de cualquier expresión de alfa-1,3-galactosiltransferasa funcional |
| JP4755174B2 (ja) | 2004-04-07 | 2011-08-24 | ザ ユニヴァーシティー オヴ シカゴ | 単量体赤色蛍光タンパク質 |
| BRPI0513826A2 (pt) | 2004-07-26 | 2010-06-22 | Dow Global Technologies Inc | processo para expressão de proteìna melhorada através de engenharia de cepa |
| ES2679282T3 (es) | 2004-10-22 | 2018-08-23 | Revivicor Inc. | Porcinos transgénicos que carecen de cadena ligera de inmunoglobulina endógena |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| EP3683230A1 (en) | 2005-05-12 | 2020-07-22 | ZymoGenetics, Inc. | Compositions and methods for modulating immune responses |
| US20090186097A1 (en) | 2005-08-09 | 2009-07-23 | David Lee Ayares | Transgenic Ungulates Expressing CTLA4-IG and Uses Thereof |
| WO2007053732A2 (en) | 2005-11-01 | 2007-05-10 | Mayo Foundation For Medical Education And Research | Promoter polymorphisms of the blys gene and use in diagnostic methods |
| US8014957B2 (en) | 2005-12-15 | 2011-09-06 | Fred Hutchinson Cancer Research Center | Genes associated with progression and response in chronic myeloid leukemia and uses thereof |
| CN101511868B (zh) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| WO2008134461A2 (en) | 2007-04-27 | 2008-11-06 | Dow Global Technologies, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
| WO2009059305A2 (en) | 2007-11-01 | 2009-05-07 | The University Of Chicago | Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation |
| WO2009073511A2 (en) | 2007-11-30 | 2009-06-11 | Mayo Foundation For Medical Education And Research | Polymorphisms of the blys gene and use in diagnostic methods |
| US8883739B2 (en) | 2010-01-19 | 2014-11-11 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
| CN102669057B (zh) * | 2011-03-18 | 2014-11-26 | 上海南方模式生物科技发展有限公司 | 一种调控动物内源基因表达的遗传修饰方法 |
| KR101948248B1 (ko) * | 2011-11-18 | 2019-02-14 | 한국생명공학연구원 | 단백질 발현 미세 조절방법 |
| US9957515B2 (en) | 2013-03-15 | 2018-05-01 | Cibus Us Llc | Methods and compositions for targeted gene modification |
| US10052364B2 (en) | 2013-03-15 | 2018-08-21 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
| US20170081674A1 (en) * | 2014-03-14 | 2017-03-23 | Cibus Us Llc | Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair |
| EP3226889A4 (en) | 2014-11-19 | 2018-11-21 | The Trustees of Columbia University in the City of New York | Osteocalcin as a treatment for frailty associated with aging |
| WO2019222359A1 (en) * | 2018-05-15 | 2019-11-21 | Duke University | Systems and methods for genetic manipulation of akkermansia species |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5024939A (en) * | 1987-07-09 | 1991-06-18 | Genentech, Inc. | Transient expression system for producing recombinant protein |
| AU635844B2 (en) | 1989-11-06 | 1993-04-01 | Cell Genesys, Inc. | Production of proteins using homologous recombination |
| US5204939A (en) * | 1989-12-14 | 1993-04-20 | Fujitsu Limited | Rule base processing system and rule evaluation control method therein |
| US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| US5641670A (en) * | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6270989B1 (en) * | 1991-11-05 | 2001-08-07 | Transkaryotic Therapies, Inc. | Protein production and delivery |
| US5561053A (en) * | 1994-08-05 | 1996-10-01 | Genentech, Inc. | Method for selecting high-expressing host cells |
| CA2364267A1 (en) * | 1999-02-19 | 2000-08-24 | Athersys, Inc. | Compositions and methods for non-targeted activation of endogenous genes |
-
1998
- 1998-09-25 JP JP2000512942A patent/JP5377806B2/ja not_active Expired - Lifetime
- 1998-09-25 NZ NZ504185A patent/NZ504185A/xx unknown
- 1998-09-25 DK DK98949508.0T patent/DK1017803T3/da active
- 1998-09-25 AU AU95816/98A patent/AU750025B2/en not_active Expired
- 1998-09-25 WO PCT/US1998/020094 patent/WO1999015650A1/en not_active Ceased
- 1998-09-25 DE DE69841723T patent/DE69841723D1/de not_active Expired - Lifetime
- 1998-09-25 EP EP98949508A patent/EP1017803B1/en not_active Expired - Lifetime
- 1998-09-25 CN CN98811571A patent/CN100582230C/zh not_active Expired - Lifetime
- 1998-09-25 KR KR1020007003195A patent/KR20010024296A/ko not_active Ceased
- 1998-09-25 CA CA2304642A patent/CA2304642C/en not_active Expired - Lifetime
- 1998-09-25 IL IL13524298A patent/IL135242A0/xx unknown
- 1998-09-25 BR BR9812540-0A patent/BR9812540A/pt not_active IP Right Cessation
- 1998-09-25 AT AT98949508T patent/ATE471373T1/de not_active IP Right Cessation
-
2000
- 2000-03-22 NO NO20001497A patent/NO20001497L/no not_active Application Discontinuation
- 2000-03-23 IL IL135242A patent/IL135242A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ATE471373T1 (de) | 2010-07-15 |
| JP5377806B2 (ja) | 2013-12-25 |
| KR20010024296A (ko) | 2001-03-26 |
| CN1280615A (zh) | 2001-01-17 |
| CN100582230C (zh) | 2010-01-20 |
| JP2003535564A (ja) | 2003-12-02 |
| HK1027375A1 (en) | 2001-01-12 |
| EP1017803B1 (en) | 2010-06-16 |
| CA2304642C (en) | 2014-11-18 |
| AU9581698A (en) | 1999-04-12 |
| DK1017803T3 (da) | 2010-08-23 |
| EP1017803A4 (en) | 2002-01-09 |
| NO20001497L (no) | 2000-05-25 |
| IL135242A0 (en) | 2001-05-20 |
| WO1999015650A9 (en) | 2000-09-08 |
| AU750025B2 (en) | 2002-07-11 |
| WO1999015650A1 (en) | 1999-04-01 |
| EP1017803A1 (en) | 2000-07-12 |
| NO20001497D0 (no) | 2000-03-22 |
| CA2304642A1 (en) | 1999-04-01 |
| NZ504185A (en) | 2003-02-28 |
| DE69841723D1 (de) | 2010-07-29 |
| IL135242A (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9812540A (pt) | Expressão de genes endógenos por recombinaçãonão homóloga de uma construção de vetor comdna celular | |
| SG141233A1 (en) | Control of gene expression | |
| Toyoda et al. | Regulation of glutathione peroxidase mRNA level by dietary selenium manipulation | |
| HUP0103485A2 (hu) | A kivánt fehérjék túlexpressziója eukarióta sejtekben, a D1 ciklin túlexpressziójával vezérelve | |
| WO2000049162A3 (en) | Compositions and methods for non-targeted activation of endogenous genes | |
| MX9606476A (es) | Inhibicion citoplasmica de expresion de genes. | |
| EP1005540A4 (en) | IKK-BETA PROTEINS, NUCLEIC ACIDS AND METHODS | |
| EP1798239A3 (en) | G-protein coupled receptors and uses therefor | |
| ATE366814T1 (de) | Gl50 moleküle, sowie verwendungen derselben | |
| WO1999020766A3 (en) | NOVEL MODIFIED NUCLEIC ACID SEQUENCES AND METHODS FOR INCREASING mRNA LEVELS AND PROTEIN EXPRESSION IN CELL SYSTEMS | |
| DE69504808D1 (de) | Corticotropin freisetzende rezeptoren des faktor 2 | |
| AU5559499A (en) | Identification of the gene causing the mouse scurfy phenotype and its human ortholog | |
| FI961202A0 (fi) | Grb3-3-geeni, sen variantteja ja niiden käyttöjä | |
| WO1999047558A3 (en) | T cell costimulatory proteins, sequences and uses thereof | |
| Calvete et al. | Venom complexity in a pitviper produced by facultative parthenogenesis | |
| DE60130465D1 (de) | Mutierte muskelspezifische enhancer | |
| Li et al. | Alternatively spliced cyclin C mRNA is widely expressed, cell cycle regulated, and encodes a truncated cyclin box | |
| Borovsky et al. | Juvenile hormone affects the splicing of Culex quinquefasciatus early trypsin messenger RNA | |
| Christophides et al. | Expression and function of the Drosophila melanogaster ADH in male Ceratitis capitata adults: a potential strategy for medfly genetic sexing based on gene‐transfer technology | |
| DE60142356D1 (de) | 18480 humane proteinkinasemoleküle und ihre verwendungen | |
| AU2001249649A1 (en) | 16836, a novel human phospholipase c family member and uses thereof | |
| WO2001092495A3 (en) | A human lysyl ixodase (47765) and uses thereof | |
| CO4790179A1 (es) | Procedimiento para la fabricacion de proteinas humanas por activacion genica endogena | |
| WO2001064904A3 (en) | 25324, 50287, 28899, 47007, and 42967 transferase family members and uses therefor | |
| WO2002006485A3 (en) | 47885, a novel human ubiquitin-activating enzyme and uses therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A,7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1890 DE 27/03/2007. |